Flags theoretical pathologic angiogenesis potential: PMC12446177 Evidence Summary Preclinical: IBD/colitis models: High remission rates, restored mucosal architecture, improved barrier function Tendon repair: Accelerated healing, improved tensile strength, reduced fibrosis Neurovascular: Sciatic nerve protection, enhanced blood vessel growth in nerve tissue Human data (emerging): Interstitial cystitis pilot (2024, n=12): 10/12 complete resolution, 2/12 at 80% improvement IV safety study (2025, n=2): no adverse effects on cardiac, hepatic, renal, or glucose biomarkers Knee pain retrospective (2021, n=17): 91.6% reported significant improvement No large-scale controlled trials published Safety: No immunosuppression or hormonal disruption in available data 2025 systematic review (HSS Journal): recommends caution due to limited high-quality clinical evidence 2025 narrative review: flags theoretical pathologic angiogenesis risk Stable in gastric acid (oral administration viable) No observed toxicity at therapeutic doses in published reports Foundational Reviews Sikiric P, Seiwerth S, et al
For example, choosing 2.5mg/mL concentration requires 2mL bacteriostatic water and delivers 250mcg per 0.1mL (10 units on a U-100 syringe)
See more The World Anti-Doping Agency (WADA) is not involved in the testing of dietary/nutritional supplements
In regard to immunotherapy, several approaches have been developed to date, including CAR-T, ADC, ADCC and nanobodies, particularly their use in CAR-T
Product works as described
